首页>投融资
Circle Pharma
D轮
Circle Pharma is a biotechnology company focused on developing cell-permeable macrocyclic peptides against therapeutic targets using computational design and synthetic chemistry.In January 2016, Circle relocated to office and laboratory space in South San Francisco, CA.In June 2021, the company raised USD 66 million in an oversubscribed Series C financing.In March 2020, the company had raised USD 45 million in a series B financing round.In December 2016, the company issued USD 4.5 million shares of Series A preferred stock in a Series A financing round. In April 2017, the series A financing comprised of USD 6.5 million shares of series A preferred stock, was closed.In January 2016, the company extended its seed funding round with an investment from ShangPharma Investment Group
基本信息
-
公司全称Circle Pharma Inc
-
类型大环肽治疗剂开发商
-
产业领域药品研发/制造、生物药、化学药
-
公司人数15~50人
-
地址280 Utah Ave Ste 100 SOUTH SAN FRANCISCO CALIFORNIA 94080-6883; US; Telephone: +16503920363;
-
联系电话8314592935
-
邮箱info@circlepharma.com
-
成立时间2012-01-01
投融资
-
2024-09-03D轮9000万美元The Column GroupNextech InvestEuclidean Capital
-
2021-06-21C轮6600万美元Nextech InvestHartford HealthCare EndowmentPavillion CapitalThe Column GroupEuclidean CapitalEli LillyPandect Bioventures
-
2020-03-17B轮4500万美元BCFNextech InvestThe Column GroupLifeForce Capital
-
2017-04-26A轮(A2)200万美元Whitesun Healthcare VenturesWI Harper GroupLifeForce CapitalElement Partners
-
2016-12-22A轮(A1)450万美元上海上药Pfizer VenturesLifeForce CapitalMission Bay Capital
-
2014-09-22种子轮未透露Pfizer VenturesMission Bay Capital
- 加载更多
相关投融资企业
D轮
Circle Pharma is a biotechnology company focused on developing cell-permeable macrocyclic peptides against therapeutic targets using computational design and synthetic chemistry.In January 2016, Circle relocated to office and laboratory space in South San Francisco, CA.In June 2021, the company raised USD 66 million in an oversubscribed Series C financing.In March 2020, the company had raised USD 45 million in a series B financing round.In December 2016, the company issued USD 4.5 million shares of Series A preferred stock in a Series A financing round. In April 2017, the series A financing comprised of USD 6.5 million shares of series A preferred stock, was closed.In January 2016, the company extended its seed funding round with an investment from ShangPharma Investment Group
A轮
Gluetacs Therapeutics is a pharmaceutical company focused on protein degradation technology
增发
Foghorn Therapeutics Inc.成立于2015年10月。该公司率先发现并开发了一类针对染色质调节系统内基因决定依赖性的药物，这是一个尚未开发的治疗机会干预。该公司专有的基因流量控制平台为其提供了一个对染色质调节系统的各个组成部分如何相互作用的综合性、机械性理解，使其能够识别、验证系统内的潜在药物靶点。
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息